LCD L36021: MolDX: Molecular Diagnostic Tests (MDT) — CGS
Policy LCD-L36021 · Clinical Laboratory
New MolDX policy effective in 2025 may alter billing processes.
Code intelligence
0005U reimbursement alerts
Policy changes, MAC LCD updates, and CMS guidance matched to code 0005U.
Elevated code riskDenied? See the governing policy
Signal breakdown
6 shown · 6 total in platform
Risk: Elevated
0
Critical
0%
6
High
100%
0
Routine
0%
0
Low
0%
New this month
—
alerts added in last 30 days
Effective soon
—
no upcoming deadlines
High
LCD L38985: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer — Palmetto GBA
Policy LCD-L38985 · Oncology
New MolDX requires billing team review.
LCD L39005: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer — Noridian
Policy LCD-L39005 · Oncology
New LCD for prostate cancer biomarkers impacts billing strategies.
LCD L36256: MolDX: Molecular Diagnostic Tests (MDT) — Noridian
Policy LCD-L36256 · Clinical Laboratory
New molecular diagnostics policy may impact billing processes.
LCD L35160: MolDX: Molecular Diagnostic Tests (MDT) — Noridian
Policy LCD-L35160 · Clinical Laboratory
New MolDX guidelines may alter MDT billing processes.
LCD L38997: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer — CGS
Policy LCD-L38997 · Urology
New LCD for prostate cancer biomarkers impacts billing.
Audit documentation
Building an audit file that includes 0005U?
The Tripwire Audit Pack exports 12 months of Clinical Laboratory policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.
Get the Clinical Laboratory audit pack — $349One-time purchase · not a subscription